sPLA₂ (human Type IIA) Polyclonal Antiserum

Zoom

Cat No: 160502

sPLA2 catalyzes the hydrolysis of phospholipids at the sn-2 position yielding a free fatty acid and a lysophospholipid.{2489} The release of arachidonic acid from membrane phospholipids by PLA2 is believed to be a key step in the control of eicosanoid...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Correlated keywords:

phospholipases arthritis inflammation antisera western blots blotting WB antibodies antiserum immunoprecipitation IP immunohistochemistry IHC immunoblotting

Product Overview:
sPLA2 catalyzes the hydrolysis of phospholipids at the sn-2 position yielding a free fatty acid and a lysophospholipid.{2489} The release of arachidonic acid from membrane phospholipids by PLA2 is believed to be a key step in the control of eicosanoid production within the cell.{1474} Human sPLA2 (Type IIA) is secreted, 14 kDa protein which is dependent on Ca2+ for optimal activity. Human sPLA2 (Type IIA) is 79% homologous to rat platelet and murine Type II sPLA2s. Cayman's sPLA2 antibody detects a band of approximately 15 kD by Western blot. For other applications, the working concentration of the antiserum must be determined empirically

Size	1 ea
Shipping	dry ice
Host	Rabbit
Antigen	Human recombinant synovial sPLA2 (Type IIA)
Application(s)	IHC, IP, and WB
Formulation	100 µl of Lyophilized antiserum
Custom Code	3822.19
UNSPSC code	12352203

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.

/ We also advise you

Cross selling for this product : sPLA<sub>2</sub> (human Type IIA) Polyclonal Antiserum There are 9 products.